Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis
NCT01452815 is registered in ClinicalTrials.gov with Tranzyme, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis
- Lead sponsor
- Tranzyme, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2011
- Completion date
- November 30, 2012
- Enrollment
- 201 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.